These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

719 related items for PubMed ID: 10965439

  • 1. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
    Samoilovich EO, Kapustik LA, Feldman EV, Yermolovich MA, Svirchevskaya AJ, Zakharenko DF, Fletcher MA, Titov LP.
    Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
    [Abstract] [Full Text] [Related]

  • 2. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R, Rahman MM, Hassan Z, Hassan MS.
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old.
    Gatchalian S, Tabora C, Bermal N, Leboulleux D, Desauziers E.
    Am J Trop Med Hyg; 2004 Mar; 70(3):273-7. PubMed ID: 15031516
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE.
    J Infect Dis; 2004 May 01; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P.
    Vaccine; 2009 Jan 14; 27(3):446-53. PubMed ID: 19007835
    [Abstract] [Full Text] [Related]

  • 10. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S.
    Bone Marrow Transplant; 2004 Jun 14; 33(12):1187-90. PubMed ID: 15077129
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM.
    Saudi Med J; 2006 Jan 14; 27(1):63-9. PubMed ID: 16432596
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 14; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
    Bhargava I, Chhaparwal BC, Phadke MA, Irani SF, Chhaparwal D, Dhorje S, Maheshwari CP.
    Indian Pediatr; 1995 Sep 14; 32(9):983-8. PubMed ID: 8935261
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM, LAIV Study Group.
    Pediatrics; 2008 Mar 14; 121(3):508-16. PubMed ID: 18310199
    [Abstract] [Full Text] [Related]

  • 16. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, Zanesco L, Cesaro S.
    Cancer; 2004 Aug 01; 101(3):635-41. PubMed ID: 15274078
    [Abstract] [Full Text] [Related]

  • 17. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM, Baker L, Starr SE, Levine BL, Books E, Plotkin SA.
    Pediatrics; 1986 Oct 01; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [Abstract] [Full Text] [Related]

  • 18. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T, McIntyre P, Roberton D, Descamps D.
    Vaccine; 2002 Dec 13; 21(3-4):281-9. PubMed ID: 12450703
    [Abstract] [Full Text] [Related]

  • 19. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P, Amstad H, Grize L, Gassner M, Takken-Sahli K, Bourquin C, Braun-Fahrländer C.
    Praxis (Bern 1994); 1999 Jun 10; 88(24):1069-77. PubMed ID: 10420798
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
    Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C.
    Southeast Asian J Trop Med Public Health; 2003 Sep 10; 34(3):589-97. PubMed ID: 15115135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.